The acquisition combines Personalis’s highly sensitive molecular residual disease (MRD) technology with Tempus’s commercial reach, multimodal data, and AI-enabled precision-oncology platform. TL;DR: Tempus AI’s proposed...read more
Category - Blog
The Dangerous Bet Behind Big Pharma’s Silence
Why dismantling America’s biomedical innovation engine is a long-term threat to the very industry staying quiet about it. A recent piece by Steven Usdain, which was also highlighted by Holden Thorp, got me thinking: are...read more
DNA Origami used to build novel vaccines
Image credit: Bannard and Howarth. (2026) Despite the current public image challenges surrounding vaccines, progress in basic science and application continues to advance rapidly. A particularly significant...read more
From Surveys to Signals: How AI Is Changing Voice of the Customer in Life Sciences
From Surveys to Signals: How AI Is Changing Voice of the Customer in Life Sciences I’ve been spending some time thinking on how Voice of the Customer (VoC) programs are evolving as artificial intelligence (AI) becomes...read more
